Payment overview · 2025
General Payments
$763.48
29 reported records · 7 companies
Healthcare provider profile · identity verified
Mandeep S Bakshi, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Sleep Medicine · GREENEVILLE, TN · NPI 1669458857
Verified facts
What the public records show
CMS Open Payments records show Mandeep S Bakshi, MD received $763.48 in general payments during 2025 across 29 reported records.
Axsome Therapeutics, Inc. accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Sunosi, Trelegy Ellipta, Xywav.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Sunosi by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 337 claims for Trelegy Ellipta by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xywav by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $273.00 | 35.8% | 12 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $271.70 | 35.6% | 8 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $79.68 | 10.4% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $68.84 | 9.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.17 | 4.6% | 2 | 2025 |
| Fisher & Paykel Healthcare Inc | Unresolved — no canonical attribution shown | $19.10 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $747.49 | 28 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $273.00 | 12 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $271.70 | 8 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $79.68 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $68.84 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| FISHER & PAYKEL HEALTHCARE Normalized: fisher paykel healthcare |
Device | Fisher & Paykel Healthcare Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Sunosi sunosi |
2025 | Sunosi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 337 | exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
337 | 69 |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 656 | 153 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 637 | 197 |
| Spiriva Respimat | Tiotropium Bromide | 388 | 98 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 337 | 69 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 317 | 77 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 177 | 41 |
| Alprazolam | Alprazolam | 125 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 114 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 18 |
| Omeprazole | Omeprazole | 109 | 32 |
| Clonazepam | Clonazepam | 93 | 14 |
| Azithromycin | Azithromycin | 92 | 33 |
| Modafinil | Modafinil | 90 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 74 | 17 |
| Spiriva Handihaler | Tiotropium Bromide | 74 | 21 |
| Doxepin Hcl | Doxepin Hcl | 71 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 43 |
| Losartan Potassium | Losartan Potassium | 67 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 14 |
| Temazepam | Temazepam | 55 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 19 |
| Zaleplon | Zaleplon | 50 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 46 | suppressed |
| Gabapentin | Gabapentin | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 13 |
| Spironolactone | Spironolactone | 43 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Armodafinil | Armodafinil | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 18 |
| Montelukast Sodium | Montelukast Sodium | 37 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | 11 |
| Azelastine Hcl | Azelastine Hcl | 29 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 14 |
| Famotidine | Famotidine | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Aralast Np | Alpha-1-Proteinase Inhibitor | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Furosemide | Furosemide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Benzonatate | Benzonatate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Neupro | Rotigotine | 17 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 16 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sunosi | Solriamfetol Hcl | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $763.48 · 29 records | Axsome Therapeutics, Inc. | BREZTRI, FISHER & PAYKEL HEALTHCARE, LUMRYZ, NUCALA, Sunosi, TRELEGY ELLIPTA, WAKIX, XYWAV | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Sunosi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error